(Total Views: 434)
Posted On: 11/01/2019 4:32:38 PM
Post# of 154140
I see your point. However, Regeneron is commercializing the drugs from their own research (as you mention, all injectables).
From their web-site: "Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases."
Maybe Regeneron would be a better candidate for partnership than for commercializing Leronlimab.
Of course IMHO, you mention very good reasons as of why it would be a good venue for selling Lero, also, they have a partnership with Sanofi (Europe operations).
If only Gilead would wake up and smell the coffee ...
From their web-site: "Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases."
Maybe Regeneron would be a better candidate for partnership than for commercializing Leronlimab.
Of course IMHO, you mention very good reasons as of why it would be a good venue for selling Lero, also, they have a partnership with Sanofi (Europe operations).
If only Gilead would wake up and smell the coffee ...
(1)
(0)
